Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)
Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
Julkaisun tekijät: Mälkönen Tarja, Nuutinen Pauliina, Hallinen Taru, Soini Erkki, Nissinen Riikka, Wennerstöm Christina, Rantanen Tapio, Hagman Johanna H., Harvima Rauno, Höök-Nikanne Johanna, Ilves Tiina, Lintu Päivi, Malanin Ken, Soramäki Iina, Tasanen Kaisa, Teho Arja, Vähävihu Katja, Itälinna Sari, Leinonen Pekka, Sarajärvi Piia, Huilaja Laura, Pasternack Rafael
Kustantaja: Medical Journals/Acta D-V
Julkaisuvuosi: 2022
Journal: Acta Dermato-Venereologica
Tietokannassa oleva lehden nimi: Acta Dermato-Venereologica
Artikkelin numero: adv00631
Volyymi: 102
eISSN: 1651-2057
DOI: http://dx.doi.org/10.2340/actadv.v101.910
Verkko-osoite: https://doi.org/10.2340/actadv.v101.910
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/175034990
Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.
Ladattava julkaisu This is an electronic reprint of the original article. |